Amylyx Pharmaceuticals (AMLX) earnings, Nov 5, 2026: EPS −3%, stock −6.1%
In brief
Amylyx Pharmaceuticals reported on Nov 5, 2026. Earnings per share changed −3% year over year, 0.3% above the estimate; revenue 0%. The stock opened with a +2.8% gap and closed the day −6.1% (Nov 5, 2026). The stock is now 32.9% below its 52-week high, +108.6% over 12 months.
EPS vs estimate+0.3%
EPS, YoY−3%
Revenue, YoY0%
Gap · day+2.8% · −6.1%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 6, 2026 | −3.4% | +10.7% |
| Nov 5, 2026 | +2.8% | −6.1% |
Next-quarter estimates, ratings and the AMLX chart are in the terminal.
Open the terminalFAQ
When is Amylyx Pharmaceuticals's next earnings report?
There is no new date in the data yet: companies announce it a few weeks ahead.
How did Amylyx Pharmaceuticals stock react to the report?
Opening gap +2.8%, day's result −6.1%.
Did Amylyx Pharmaceuticals's earnings grow?
Earnings per share fell 3% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.